Carbonyl Reductase Expression and Its Clinical Significance in Non–Small-Cell Lung Cancer

Carbonyl reductase (CBR) is a cytosolic NADPH-dependent oxidoreductase metabolizing prostaglandins, steroids, quinines, and anthracycline antibiotics. Many experimental studies have shown that CBR plays important roles in the regulation of tumor progression, but clinical significance of CBR status remains unclear. Thus, we conducted a retrospective study on CBR mRNA expression in lung cancer. Tumor tissues obtained from 59 non–small-cell lung cancer patients were analyzed by quantitative real-time reverse transcription-PCR assay to reveal clinical significance of CBR expression. Angiogenesis was measured immunohistochemically as intratumoral microvessel density (IMVD) using anti-CD34 monoclonal antibody CD34-IMVD) and anti-CD105 monoclonal antibody (CD105-IMVD). CBR mRNA expression was significantly reduced along with progression of primary tumors (the mean CBR mRNA/GAPDH mRNA, 3.288 × 10−2 for pT1, 1.628 × 10−2 for pT2, and 1.175 × 10−2 for pT3-4 disease, respectively; P = 0.02). Moreover, CBR mRNA expression in tumor with nodal involvement seemed to be reduced as compared with that in tumor without nodal involvement (the mean CBR mRNA/GAPDH mRNA, 1.446 × 10−2 and 2.531 × 10−2, respectively), whereas the difference did not reach a statistical significance (P = 0.09). The mean CD105-IMVD for CBR-high tumor was 59.2, which was significantly lower than that for CBR-low tumor (130.6, P = 0.02), whereas no significant difference between the mean CD34-IMVDs for CBR-high tumor and CBR-low tumor was found. The 5-year survival rate of CBR-high patients was 68.3%, significantly higher than that of CBR-low patients (36.5%; P = 0.03). A multivariate analysis confirmed that CBR-high expression was a significant factor to predict a favorable prognosis (P = 0.04; relative risk, 0.39; 95% confidence interval, 0.16-0.98). Expression of CBR mRNA was a significant prognostic factor in non–small-cell lung cancer and was inversely associated with tumor progression and angiogenesis.

[1]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Castelao,et al.  Lung cancer and cyclooxygenase-2. , 2003, The Annals of thoracic surgery.

[3]  M. Dohadwala,et al.  Autocrine/Paracrine Prostaglandin E2 Production by Non-small Cell Lung Cancer Cells Regulates Matrix Metalloproteinase-2 and CD44 in Cyclooxygenase-2-dependent Invasion* , 2002, The Journal of Biological Chemistry.

[4]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[5]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[6]  A. Tarnawski,et al.  Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.

[7]  H. Wada,et al.  Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  S. Tsuchida,et al.  Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer , 2001, British Journal of Cancer.

[9]  T. Moody,et al.  Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. , 2001, Lung cancer.

[10]  H. Wada,et al.  Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[11]  S. Tsuchida,et al.  Carbonyl reductase: a novel metastasis-modulating function. , 2000, Cancer research.

[12]  S. Kumar,et al.  Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. , 1999, Cancer research.

[13]  Li Zhu,et al.  Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. , 1998, Cancer research.

[14]  J. Morrow,et al.  Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. , 1998, Cancer research.

[15]  M. Kelner,et al.  Heterologous expression of carbonyl reductase: demonstration of prostaglandin 9-ketoreductase activity and paraquat resistance. , 1997, Life sciences.

[16]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[17]  C. Bernabéu,et al.  EDITORIAL. CD105 AND ANGIOGENESIS , 1996 .

[18]  Yung‐Chie Lee,et al.  Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. , 1995, American journal of respiratory and critical care medicine.

[19]  J. Doroshow,et al.  Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. , 1995, Cancer research.

[20]  E. Maser,et al.  Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases. , 1995, Biochemical pharmacology.

[21]  S. Rodan,et al.  Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. , 1994, The Journal of clinical investigation.

[22]  B. Wermuth,et al.  Immunohistochemical localization of carbonyl reductase in human tissues. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  C. Angeletti,et al.  Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.

[24]  A. Schieber,et al.  Purification and properties of prostaglandin 9-ketoreductase from pig and human kidney. Identity with human carbonyl reductase. , 1992, European journal of biochemistry.

[25]  A. Fulton,et al.  Role of the prostaglandin E2 receptor in mammary tumor metastasis. , 1991, Cancer research.

[26]  F. Oesch,et al.  Carbonyl reductase provides the enzymatic basis of quinone detoxication in man. , 1986, Biochemical pharmacology.

[27]  G. Forrest,et al.  Carbonyl reductase. , 2000, Chemico-biological interactions.

[28]  M. Hayakari,et al.  Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas , 1999, Journal of Cancer Research and Clinical Oncology.